journal article·2025-04-23Open access

Injectable Stem Cell-Based Therapies for Myocardial Regeneration: A Review of the Literature

Marissa Guo, Tatsuya Watanabe, Toshiharu Shinoka

Abstract

Stem cell-based therapies are an emerging treatment modality aimed at replenishing lost cardiomyocytes and improving myocardial function after cardiac injury. This review examines the current state of research on injectable stem cell therapies in the setting of cardiovascular disease given their relative simplicity and ability for deep myocardial tissue penetration. Various methods of cell delivery, ranging in level of invasiveness and procedural complexity, have been developed, and numerous cell types have been studied as potential sources of stem cells, each with distinct advantages and disadvantages. We discuss key challenges associated with this approach, including low stem cell retention after transplantation and the innovative biomolecular strategies that have been explored to address this issue. Overall, investigations into the application of stem cells toward cardiac regeneration remain predominantly in the preclinical stage with a number of small, early-phase clinical trials. However, continued scientific advancements in stem cell technology may provide transformative treatment options for patients with heart failure, offering improved survival and quality of life.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · Mesenchymal stem cell research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

Department of Cardiothoracic Surgery, Nationwide Children’s Hospital, Columbus, OH 43205, USA

References (100+)

Show source-provided references
1. Ischemic cardiomyopathy: Epidemiology, pathophysiology, outcomes, and therapeutic options10.1007/s10741-023-10377-4 ↗
2. Cardiac replacement therapy: Critical issues and future perspectives of heart transplantation and artificial heart10.1016/j.cpcardiol.2024.102971 ↗
3. Mammalian heart renewal by pre-existing cardiomyocytes10.1038/nature11682 ↗
4. Adult cardiac stem cells are multipotent and support myocardial regeneration10.1016/S0092-8674(03)00687-1 ↗
5. Evidence for cardiomyocyte renewal in humans10.1126/science.1164680 ↗
6. Watanabe, T., Hatayama, N., Guo, M., Yuhara, S., and Shinoka, T. (2024). Bridging the Gap: Advances and Challenges in Heart Regeneration from In Vitro to In Vivo Applications. Bioengineering, 11.10.3390/bioengineering11100954 ↗
7. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials10.1161/CIRCULATIONAHA.104.526749 ↗
8. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery10.1016/j.athoracsur.2008.08.068 ↗
9. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial10.1161/CIRCRESAHA.114.303180 ↗
10. Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: A prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass10.1016/j.healun.2014.02.009 ↗
11. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: Preliminary results10.1055/s-2007-989351 ↗
12. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial10.1001/jama.2012.25321 ↗
13. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial10.1001/jama.2012.418 ↗
14. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics10.1016/j.jacc.2013.02.071 ↗
15. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial10.1001/jama.2013.282909 ↗
16. Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: A randomized placebo-controlled trial (END-HF)10.1007/s12265-014-9580-6 ↗
17. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: Final 4-year follow-up of the MSC-HF trial10.1002/ejhf.1700 ↗
18. Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell transplantation10.1016/S0735-1097(03)00397-8 ↗
19. Transvenous intramyocardial cellular delivery increases retention in comparison to intracoronary delivery in a porcine model of acute myocardial infarction10.1111/j.1540-8183.2008.00390.x ↗
20. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction10.1007/s00395-008-0741-0 ↗
21. Intravenous xenogeneic transplantation of human adipose-derived stem cells improves left ventricular function and microvascular integrity in swine myocardial infarction model10.1002/ccd.25566 ↗
22. Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction10.1186/s13287-018-0888-z ↗
23. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction10.1016/j.jacc.2009.06.055 ↗
24. Monitoring of bone marrow cell homing into the infarcted human myocardium10.1161/01.CIR.0000163546.27639.AA ↗
25. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction
26. Stem Cell Homing: A Potential Therapeutic Strategy Unproven for Treatment of Myocardial Injury10.1007/s12265-018-9823-z ↗
27. CSF2RB overexpression promotes the protective effects of mesenchymal stromal cells against ischemic heart injury10.7150/thno.81336 ↗
28. Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose10.1161/JAHA.117.007400 ↗
29. Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction10.1002/sctm.19-0013 ↗
30. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans10.1161/01.CIR.0000034046.87607.1C ↗
31. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction10.1056/NEJMoa055706 ↗
32. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: Insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial10.1093/eurjhf/hfp113 ↗
33. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction10.1161/CIRCHEARTFAILURE.108.843243 ↗
34. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: Results of the randomized controlled HEBE trial10.1093/eurheartj/ehq449 ↗
35. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function10.1161/CIRCULATIONAHA.112.001035 ↗
36. Intracoronary autologous bone marrow cell transfer after myocardial infarction: The BOOST-2 randomised placebo-controlled clinical trial10.1093/eurheartj/ehx188 ↗
37. Sheng, C.C., Zhou, L., and Hao, J. (2013). Current stem cell delivery methods for myocardial repair. Biomed. Res. Int., 2013.10.1155/2013/547902 ↗
38. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis10.1161/CIRCRESAHA.117.311466 ↗
39. Intracoronary transplantation of pluripotent stem cell-derived cardiomyocytes: Inefficient procedure for cardiac regeneration10.1016/j.yjmcc.2022.11.004 ↗
40. One-year follow-up of transcoronary sinus administration of autologous bone marrow in patients with chronic refractory angina10.1016/j.carrev.2005.08.002 ↗
41. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction10.1007/s00395-005-0521-z ↗
42. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction10.1016/j.ejcts.2006.11.057 ↗
43. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention10.1136/hrt.2005.069799 ↗
44. Impact of timing on efficacy and safetyof intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: A pooled subgroup analysis of randomized controlled trials10.1002/clc.20575 ↗
45. Cardiac progenitor/stem cells on myocardial infarction or ischemic heart disease: What we have known from current research10.1007/s10741-013-9372-0 ↗
46. Cardiac Stem Cell Treatment in Myocardial Infarction: A Systematic Review and Meta-Analysis of Preclinical Studies10.1161/CIRCRESAHA.115.307676 ↗
47. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: Surgical aspects and interim analysis of myocardial function and viability by magnetic resonance10.1161/CIRCULATIONAHA.112.092627 ↗
48. The Lancet Editors (2019). Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet, 393, 1084.10.1016/S0140-6736(19)30542-2 ↗
49. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction)10.1016/j.jacc.2013.08.724 ↗
50. Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial10.1136/openhrt-2021-001614 ↗
51. Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial10.1161/CIRCRESAHA.116.310253 ↗
52. Transplanted adult bone marrow cells repair myocardial infarcts in mice10.1111/j.1749-6632.2001.tb03592.x ↗
53. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart10.1161/hc0102.101442 ↗
54. Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects10.1016/S0003-4975(02)03517-8 ↗
55. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: The Cardio133 trial10.1093/eurheartj/ehu007 ↗
56. Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury10.1080/14653240510027226 ↗
57. Cardiac progenitor cells in brown adipose tissue repaired damaged myocardium10.1016/j.bbrc.2006.01.181 ↗
58. Adipose-derived Mesenchymal Stem Cells and Their Reparative Potential in Ischemic Heart Disease10.1016/j.recesp.2015.02.025 ↗
59. Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction10.1097/00029330-200702020-00009 ↗
60. Therapeutic potential of human adipose stem cells in a rat myocardial infarction model10.3349/ymj.2010.51.1.69 ↗
61. Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents10.1016/j.yjmcc.2010.08.010 ↗
62. Adipose-derived stromal cell therapy improves cardiac function after coronary occlusion in rats10.3727/096368912X636858 ↗
63. Adipose-derived stem cells from both visceral and subcutaneous fat deposits significantly improve contractile function of infarcted rat hearts10.3727/096368914X685780 ↗
64. The effect of bone marrow- and adipose tissue-derived mesenchymal stem cell transplantation on myocardial remodelling in the rat model of ischaemic heart failure10.1111/iep.12017 ↗
65. Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction10.3727/096368912X638847 ↗
66. Adipose tissue-derived cells improve cardiac function following myocardial infarction10.1016/j.jss.2008.03.019 ↗
67. IFATS collection: Human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function10.1634/stemcells.2008-0273 ↗
68. Tracking long-term survival of intramyocardially delivered human adipose tissue-derived stem cells using bioluminescence imaging10.1007/s11307-010-0392-z ↗
69. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial10.1016/j.ahj.2014.03.022 ↗
70. Human umbilical cord mesenchymal stem cells: A new era for stem cell therapy10.3727/096368915X686841 ↗
71. Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms10.1186/scrt394 ↗
72. Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction10.3727/096368912X657675 ↗
73. Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction10.1097/MCA.0b013e3283640f00 ↗
74. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure10.1161/CIRCRESAHA.117.310712 ↗
75. Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation10.1016/j.biomaterials.2011.11.087 ↗
76. Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat10.1016/j.yjmcc.2006.12.008 ↗
77. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes10.1097/01.TP.0000149503.92433.39 ↗
78. Cellular cardiomyoplasty with human amniotic fluid stem cells: In vitro and in vivo studies10.1089/ten.tea.2009.0728 ↗
79. In vivo differentiation of human amniotic epithelial cells into cardiomyocyte-like cells and cell transplantation effect on myocardial infarction in rats: Comparison with cord blood and adipose tissue-derived mesenchymal stem cells10.3727/096368912X653039 ↗
80. Small extracellular vesicles secreted from human amniotic fluid mesenchymal stromal cells possess cardioprotective and promigratory potential10.1007/s00395-020-0785-3 ↗
81. Exosomes derived from human amniotic fluid mesenchymal stem cells alleviate cardiac fibrosis via enhancing angiogenesis in vivo and in vitro10.21037/cdt-20-1032 ↗
82. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates10.1172/JCI40120 ↗
83. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: A preclinical study10.1016/S0140-6736(05)67380-1 ↗
84. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts10.1016/j.jacc.2007.07.054 ↗
85. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells10.1038/nbt1014 ↗
86. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: Insights into the development of cell-based pacemakers10.1161/01.CIR.0000151313.18547.A2 ↗
87. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts10.1038/nbt1327 ↗
88. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts10.1038/nature13233 ↗
89. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates10.1038/nbt.4162 ↗
90. Lack of Remuscularization Following Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitor Cells in Infarcted Nonhuman Primates10.1161/CIRCRESAHA.117.311578 ↗
91. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction10.1016/j.jacc.2017.11.047 ↗
92. Funakoshi, S., Miki, K., Takaki, T., Okubo, C., Hatani, T., Chonabayashi, K., Nishikawa, M., Takei, I., Oishi, A., and Narita, M. (2016). Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Sci. Rep., 6.10.1038/srep19111 ↗
93. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts10.1038/nature19815 ↗
94. Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy10.1016/j.stem.2023.04.010 ↗
95. Combined Treatment of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Endothelial Cells Regenerate the Infarcted Heart in Mice and Non-Human Primates10.1161/CIRCULATIONAHA.122.061736 ↗
96. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients10.1038/s41587-019-0016-3 ↗
97. How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart?10.1155/2016/9682757 ↗
98. Non-invasive in vivo imaging of cardiac stem/progenitor cell biodistribution and retention after intracoronary and intramyocardial delivery in a swine model of chronic ischemia reperfusion injury10.1186/s12967-017-1157-0 ↗
99. Injectable biopolymers enhance angiogenesis after myocardial infarction10.1089/ten.2005.11.1860 ↗
100. Danoviz, M.E., Nakamuta, J.S., Marques, F.L.N., dos Santos, L., Alvarenga, E.C., dos Santos, A.A., Antonio, E.L., Schettert, I.T., Tucci, P.J., and Krieger, J.E. (2010). Rat adipose tissue-derived stem cells transplantation attenuates cardiac dysfunction post infarction and biopolymers enhance cell retention. PLoS ONE, 5.10.1371/journal.pone.0012077 ↗